Early treatment of complex located pediatric low‐grade gliomas using iodine‐125 brachytherapy alone or in combination with microsurgery

Kunz, Mathias; Nachbichler, Silke Birgit; Ertl, Lorenz; Fesl, Gunther; Egensperger, Rupert; Niyazi, Maximilian; Schmid, Irene; Tonn, Joerg C.; Peraud, Aurelia; Kreth, Friedrich W.

doi:10.1002/cam4.605

Cited by 17 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The considered patients were treated with 50-65 Gy cumulative therapeutic dose delivered within 9 months. Kunz et al [96] reported similar results in a clinical study performed on 58 pediatric patients. SBT alone was performed on patients with LGG of ≤ 4 cm in diameter.…”

Section: Brachytherapy Dosimetry In Pediatric Therapy Applicationssupporting

confidence: 52%

“…Clinical Experience With BT in Pediatrics: The largest clinical experience with BT in pediatrics has been reported for soft-tissue sarcoma [94], [97], [99], [100]. Furthermore, clinical trials on patients with solid tumors [95], lowgrade gliomas [96], [101], and genital cancer-for both male [93] and female [98] pediatric populations-have been published. Merchant et al [99] have reported on the treatment of soft-tissue sarcoma with BT alone or as boost to EBRT.…”

Section: Brachytherapy Dosimetry In Pediatric Therapy Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

A Review on Personalized Pediatric Dosimetry Applications Using Advanced Computational Tools

Papadimitroulas

Balomenos²,

Kopsinis³

et al. 2019

IEEE Trans. Radiat. Plasma Med. Sci.

View full text Add to dashboard Cite

Pediatric patient-specific dosimetry of ionizing radiation is of great scientific and social interest. Children provide a higher relative cancer-risk from exposure to ionizing radiation compared to adults. The proposed study reviews the recent techniques applied in pediatric imaging and therapy applications for dosimetry purposes. Modern medicine makes use of advance computational tools for the personalization of internal and external dosimetry, especially in the sensitive group of children. Several groups of pediatric computational models have been developed which are combined with Monte Carlo (MC) simulations, machine learning (ML) techniques, and image processing algorithms for accurate dosimetry assessment. More specifically, this paper reviews the dosimetry applications in pediatric diagnostic procedures, including computed tomography and nuclear medicine applications. Right afterward, the most recent applications in therapeutic brachytherapy protocols are presented, which is a rather sensitive procedure in pediatrics. Finally, modern tools for dosimetry optimization are discussed, reviewing the most indicative applications with: 1) MC simulations for Manuscript

show abstract

Section: Brachytherapy Dosimetry In Pediatric Therapy Applicationssupporting

confidence: 52%

Section: Brachytherapy Dosimetry In Pediatric Therapy Applicationsmentioning

confidence: 99%

A Review on Personalized Pediatric Dosimetry Applications Using Advanced Computational Tools

Papadimitroulas

Balomenos²,

Kopsinis³

et al. 2019

IEEE Trans. Radiat. Plasma Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Currently glioma treatments have shown low effectiveness for the outcome of patients with glioma, which have emphasized the need for new molecularly targeted therapies ( 11 , 13 ). Gliomas are aggressive and their incidence rate in patients is increasing, resulting in a relative high mortality rate ( 13 , 14 ). Previous reports have suggested that TUN may have crucial roles in inhibiting tumor growth and enhancing apoptosis mediated by tumor necrosis factor-related ligands ( 7 , 8 ).…”

Section: Discussionmentioning

confidence: 99%

Tunicamycin inhibits progression of glioma cells through downregulation of the MEG‑3‑regulated wnt/β‑catenin signaling pathway

Xue

Qin

2018

Oncol Lett

View full text Add to dashboard Cite

Glioma is derived from the oncogenic transformation of brain and spinal cord glial cells, and is one of the most common primary brain tumors. Tunicamycin (TUN) can significantly inhibit glioma growth and aggressiveness by promoting apoptosis in glioma cells. The purpose of the present study was to investigate the effects of TUN on growth of glioma cells and examine the TUN-mediated signaling pathway. The inhibitory effects of TUN on apoptosis, growth, aggressiveness and cell cycle arrest of glioma tumor cells were determined by western blotting, reverse transcription-quantitative polymerase chain reaction, apoptotic assays and immunofluorescence. The results demonstrated that treatment with TUN suppressed growth, migration and invasion of glioma carcinoma cells. In addition, TUN treatment induced apoptosis of glioma cells through downregulation of Bcl-2 and P53 expression levels. Findings also indicated that TUN suppressed proliferation and arrested the glioma cells in the S phase of the cell cycle. Further analysis of the mechanisms of TUN demonstrated that TUN treatment upregulated the expression levels of maternally expressed gene (MEG)-3, wnt and β-catenin in glioma cells. Furthermore, knockdown of MEG-3 expression reversed the TUN-decreased wnt/β-catenin signaling pathway, which subsequently also reversed the TUN-inhibited growth and aggressiveness of glioma cells. In conclusion, the findings in the present study indicated that TUN treatment inhibited growth and aggressiveness through MEG-3-mediated wnt/β-catenin signaling, suggesting that TUN may be an efficient anticancer agent for the treatment of glioma.

show abstract

“…Currently, the antiglioma therapies, including chemoradiotherapy and biotherapy are efficient for patients with cancer (17,18). Incidence rates of gliomas are increasing (19,20). Evidence suggests that tunicamycin may inhibit tumor growth and promote apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand (10,21).…”

Section: Discussionmentioning

confidence: 99%

MEG‑3‑mediated Wnt/β‑catenin signaling pathway controls the inhibition of tunicamycin‑mediated viability in glioblastoma

et al. 2018

View full text Add to dashboard Cite

Glioblastoma is the most common primary brain carcinoma and leads to a poor survival rate of patients worldwide. Results of previous studies have suggested that tunicamycin may inhibit aggressiveness by promoting apoptosis of glioblastoma cells. In the present study, the effects of tunicamycin and its potential molecular mechanisms underlying the viability and aggressiveness of glioblastoma cells were investigated. Western blot analysis, the reverse transcription-quantitative polymerase chain reaction, immunohistochemistry, apoptosis assays and immunofluorescence were employed to examine the effects of tunicamycin on apoptosis, viability, aggressiveness and cell cycle arrest of glioblastoma cells by downregulation of the expression levels of fibronectin and epithelial cadherin. In vitro experiments demonstrated that tunicamycin significantly inhibited the viability, migration and invasion of glioblastoma cells. Results demonstrated that tunicamycin administration promoted apoptosis of glioblastoma cells through the upregulation of poly(ADP-ribose) polymerase and caspase-9. Cell cycle assays revealed that tunicamycin suppressed the proliferation of, and induced cell cycle arrest at S phase in, glioblastoma cells. Additionally, tunicamycin increased the expression of maternally expressed gene-3 (MEG-3) and wingless/integrated (Wnt)/β-catenin in glioblastoma cells. Results also indicated that tunicamycin administration promoted the Wnt/β-catenin signaling pathway in glioblastoma cells. Knockdown of MEG-3 inhibited tunicamycin-mediated downregulation of the Wnt/β-catenin signaling pathway, which was inhibited further by tunicamycin-mediated inhibition of viability and aggressiveness in glioblastoma. In vivo assays demonstrated that tunicamycin treatment significantly inhibited tumor viability and promoted apoptosis, which further led to an increased survival rate of tumor-bearing mice compared with that of the control group. In conclusion, these results indicate that tunicamycin may inhibit the viability and aggressiveness by regulating MEG-3-mediated Wnt/β-catenin signaling, suggesting that tunicamycin may be a potential anticancer agent for glioblastoma therapy.

show abstract

Early treatment of complex located pediatric low‐grade gliomas using iodine‐125 brachytherapy alone or in combination with microsurgery

Cited by 17 publications

References 38 publications

A Review on Personalized Pediatric Dosimetry Applications Using Advanced Computational Tools

A Review on Personalized Pediatric Dosimetry Applications Using Advanced Computational Tools

Tunicamycin inhibits progression of glioma cells through downregulation of the MEG‑3‑regulated wnt/β‑catenin signaling pathway

MEG‑3‑mediated Wnt/β‑catenin signaling pathway controls the inhibition of tunicamycin‑mediated viability in glioblastoma

Contact Info

Product

Resources

About